Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Other equities analysts have also issued research reports about the company. Lake Street Capital reduced their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright reduced their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $0.65 on Friday. Ekso Bionics has a 52 week low of $0.50 and a 52 week high of $3.13. The business’s 50 day moving average price is $0.76 and its 200 day moving average price is $0.99. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The firm has a market cap of $14.28 million, a P/E ratio of -1.00 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same period last year, the company earned ($0.24) earnings per share. On average, sell-side analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.